EGFR and non-small cell lung carcinoma: Although there is currently no ctDNA-based diagnostic tool for SCLC on the market, the FDA approved Guardant360 CDx as a companion diagnostic for NSCLC patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with osimertinib (Tagrisso) in August 2020 [98].